3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
7
Fluorouracil
7
Leucovorin
6
pembrolizumab
4
Paclitaxel
4
Capecitabine
4
Radiotherapy
3
Radiation
3
Nivolumab
3
Cisplatin
3
zimberelimab
2
tislelizumab
2
durvalumab
2
Trastuzumab
2
Taxes
2
Levoleucovorin
2
Irinotecan
2
zanidatamab
1
tucatinib
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trastuzumab deruxtecan
1
spartalizumab
1
quemliclustat
1
obinutuzumab
1
naptumomab estafenatox
1
lenvatinib
1
futibatinib
1
dehydroftorafur
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Adenocarcinoma Of Esophagus
×
zanidatamab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled